---- Click on the presentation title to view the full abstract ----
| 17:00 | Adalimumab biosimilars have similar disease relapse rates to originator adalimumab when treating non-infectious uveitis | | TOMKINS-NETZER O, SHARON Y, NIEDERER R, AMAR R, SAR S, HABOT-WILNER Z, GEPSTEIN R, SHYRIAIEVA H, DIAB R, CORREDORES J, COHEN S, BARNETT-GRINESS O, KRAMER M |
| 17:07 | Real-World Outcomes of Fluocinolone Acetonide Implant for Non-Infectious Uveitis: Experience from a Tertiary Centre in Portugal | | FONSECA C, MACHADO T |
| 17:14 | Long-term Efficacy and Safety of Intravitreal ILUVIEN® for Non-Infectious Uveitis - A Retrospective Analysis | | GOUVEIA P, VAZ PEREIRA M, FERNANDES T, MENDONçA L, SOUSA K, MESQUITA MARQUES P |
| 17:21 | Retreatment Criteria in Fluocinolone Acetonide implant treated Non-Infectious Uveitis (NIU) | | TUCKER W, PAVESIO C, TESTI I, REES A, WESTCOTT M, PETRUSHKIN H, CHU C, GURBAXANI A, ADDISON P |
| 17:28 | Association of anti-adalimumab antibodies with ocular inflammation in the management of autoimmune diseases | | EL FEQI D, ELARABY O, HUNG J H, NGUYEN Q D |
| 17:35 | Systemic Immunomodulatory Therapy in the Uveitis Clinic: 10-year profile | | FERREIRA AM, SILVA M, PEDROSA C, OLIVEIRA-FERREIRA C, TORRES-COSTA S, TORRãO L, FIGUEIRA L, RODRIGUES-ARAúJO J |
| 17:42 | Real-World Treatment Patterns and Ocular Morbidity in Patients with Uveitic Macular Edema (UME) Secondary to Non-Infectious Uveitis (NIU) in the United States (US) | | NGUYEN QD, CHEN L, DAYAL P, PAL N, STOILOV I, MESQUIDA M, HASKOVA Z, STEEPLES L |
| | 17:49 | Closing Remarks | |
| | 17:53 | End of Session | |